Compare ARGX & VLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARGX | VLO |
|---|---|---|
| Founded | 2008 | 1980 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Integrated oil Companies |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4B | 77.3B |
| IPO Year | 2017 | 1997 |
| Metric | ARGX | VLO |
|---|---|---|
| Price | $846.25 | $341.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 18 |
| Target Price | ★ $1,008.56 | $232.17 |
| AVG Volume (30 Days) | 272.9K | ★ 2.5M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.91% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 16.78 |
| Revenue | N/A | ★ $122,687,000,000.00 |
| Revenue This Year | $44.39 | $9.62 |
| Revenue Next Year | $20.84 | N/A |
| P/E Ratio | $33.69 | ★ $20.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $650.01 | $135.02 |
| 52 Week High | $953.58 | $343.73 |
| Indicator | ARGX | VLO |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 72.66 |
| Support Level | $833.82 | $292.79 |
| Resistance Level | $851.88 | N/A |
| Average True Range (ATR) | 21.60 | 11.73 |
| MACD | -1.45 | 2.22 |
| Stochastic Oscillator | 29.53 | 91.10 |
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Valero Energy is one of the largest independent refiners in the United States. It operates 15 refineries, with a total throughput capacity of 3.2 million barrels a day in the US, Canada, and the United Kingdom. Valero also owns 12 ethanol plants with capacity of 1.6 billion gallons a year and holds a 50% stake in Diamond Green Diesel, which can produce 1.2 billion gallons per year of renewable diesel.